Home > Blog Tag

Blog Posts by Tag: COVID-19

Is the FDA on a Dangerous Path? Overstepping LDT Authority Hampered COVID Response and Has Long Term Consequences for US Healthcare

As I recently discussed during my session at this year’s Executive War College, one important aspect of the COVID pandemic and laboratory testing during this time is how it exemplified the detrimental consequences of FDA overreach — which contributed in large part to testing delays and a hamstrung response in the outbreak’s early days — and how that overstepping poses risk going forward. On...

Read


Insurers Not Required to Reimburse COVID-19 Tests for Returning Workers

According to newly released guidelines from the Trump Administration, insurers will not have to cover COVID-19 screening tests mandated by employers for returning employees.Until these new guidelines, The Families First Coronavirus Response Act required insurers to cover COVID-19 testing without patient cost-sharing. The latest announcement said the law applies only to tests considered medically...

Read


XIFIN Data Reveals That COVID-19 Antibody Testing Volumes Are Surprisingly Low

Antibody testing volumes are lower than expected, while lab testing volumes have rebounded since March 2020, according to XIFIN data shared at a recent UBS audio conference. XIFIN’s Executive Chair and CEO Lâle White and Executive VP and General Manager of Diagnostic Services Kyle Fetter were on hand to share updates on nationwide COVID-19 testing and payor behavior. “COVID-19 has...

Read


Don’t Let a Crisis Misguide Your Choice in Revenue Cycle Management Systems for Outreach or Outpatient Labs

Hospital outreach program leaders are very familiar with management from the hospital or health system proposing that the current electronic health record (EHR) system is sufficient to support the outreach and outpatient laboratory revenue cycle management (RCM) process. “It’ll save money,” they say. “They (the vendor) tell us that it works fine for outreach and outpatient lab claims,” they add....

Read


CMS Has Largest-Ever Public Meeting – Discusses Pricing Lab Test Codes

On June 22, 2020, CMS held its largest-ever annual public meeting for pricing new laboratory test codes. In addition, it was the first-ever meeting held only virtually. Nearly 30 different organizations offered comments on some 130 new codes. A full transcript of the meeting is available at the blog “Discoveries in Health Policy.” The blog’s author, Bruce Quinn MD PhD, told XIFIN...

Read


COVID-19 Puts a Spotlight on Billing DIY versus Outsourcing

As the economy starts to reopen and elective healthcare activities increase, hospital ancillary services, outreach programs, pathology practices, IDTF/remote patient monitoring companies, and independent labs must be ready to handle the volume surge. XIFIN’s Lab Volume Index data indicates a steady upward trend in lab volume; routine testing has already rebounded to nearly 80% of pre-COVID levels...

Read


How Laboratories Can Prepare for Coronavirus Coding and Billing Issues

Enjoy the following content from our partner, Infinx. However you feel about the current response to COVID-19, few people ever really expected to be here. We hold emergency preparedness drills and assign “essential personnel” status, but the scope of what we face seems too inconceivable. So now, we must balance providing the care and testing the community needs with collecting the...

Read


Routine Lab Volume in the US Sees Steep Drop, Gradual Recovery Due to COVID-19

Diagnostic laboratories remain at the forefront of US efforts to assess and control the spread of COVID-19. Diagnostics play a critical role both in the US pandemic response and also in helping the country as states establish plans to re-open. As states, and therefore laboratories, continue to focus on COVID-19 virus testing with the recent addition of antibody testing, elective and non-urgent...

Read